The rapid maturation of nucleic acid therapeutics and complex biologics has necessitated a significant shift in the pharmaceutical quality paradigm. Traditional “one-size-fits-all” approaches are increasingly inadequate for modalities like messenger RNA (mRNA), antisense oligonucleotides, and viral vectors, where the structural complexity and inherent instability of the molecule dictate the efficacy of the final drug product. Developing a robust quality control program for these next-generation therapies requires a deep integration of risk-based science and advanced analytical instrumentation. As therapeutic pipelines transition from discovery to the clinic, the implementation of a quality control procedure that is “fit-for-purpose” (meaning it is specifically designed to address the critical quality attributes (CQAs) of the molecule in its specific biological context) becomes the primary determinant of regulatory success and patient safety.
Quality control challenges in biologics and nucleic acid therapeutics
The fundamental obstacles in the nucleic acid-related therapy sector stem from complex molecular structures and extreme sensitivity to manufacturing conditions. For RNA-based products, implementing a Quality by Design (QbD) framework is essential to systematically assess CQAs, yet achieving rapid, disease-agnostic platform production remains a significant hurdle. Similarly, protein therapeutics face difficulties in monitoring multiple site-specific quality attributes simultaneously. While mass spectrometry-based multi-attribute methods (MAM) offer a sophisticated solution for characterizing nucleic acid-based therapeutics, they require overcoming substantial implementation and regulatory hurdles to be fully integrated into a quality control procedure.
Advanced modalities like gene therapies and cell-derived secretomes introduce further layers of complexity into a quality control program. Recombinant adeno-associated virus (rAAV) products frequently encounter challenges in the high-throughput quantification of virus titer, capsid content, and aggregation, areas where analytical methods are still largely underdeveloped. Furthermore, biologics such as secretomes exhibit high variability in bioactive components, necessitating robust Quality Control (QC) procedures for their manufacturing and stability testing to ensure batch-to-batch consistency. Addressing these QC challenges demands the integration of lifecycle management and advanced process control strategies to meet regulations and ensure product efficacy.
Designing fit-for-purpose QC protocols: Principles and practical considerations
Designing effective quality control protocols requires a systematic approach aligning analytical methods with the product’s CQAs and intended use. Utilizing an Analytical Quality by Design (AQbD) framework supports the development of robust, lifecycle-managed assays that ensure reliable data while managing scientific uncertainty. Practical considerations involve selecting technologies that balance scientific rigor with operational feasibility, such as:
- Technology selection: Implementing MAM for proteins to monitor site-specific attributes or emerging high-throughput methods for viral titer and capsid content in gene therapies.
- Risk-based lifecycle management: Evolving the quality control procedure manual from early-phase qualified assays to late-phase validated methods as the program progresses.
- Regulatory integration: Incorporating real-world evidence and regulatory feedback to refine quality control checking procedures to meet specific regulatory agency expectations.
This progressive strategy allows biotechs to maintain agility while ensuring quality control procedures remain robust throughout development. By prioritizing data quality and validation early, developers mitigate the risk of late-stage Chemistry, Manufacturing, and Controls (CMC) delays, ensuring the quality control program remains audit-ready during a Biologics License Application (BLA).
Analytical methods and validation strategies for advanced therapeutic modalities
The technical backbone of modern quality control best practices lies in high-resolution analytical instrumentation. For nucleic acid-based therapeutics, Liquid Chromatography-Mass Spectrometry (LC-MS), specifically Ultra-High Performance Liquid Chromatography (UPLC), has emerged as the gold standard for verifying sequence identity and identifying site-specific modifications, with ion-pairing-free strategies evolving as key tools for bioanalysis. These quality control procedures are essential for ensuring that every batch of a synthetic oligonucleotide or mRNA-based vaccine meets predefined specifications.
Key methodologies in a modern QC lab include:
- Orthogonal LNP-RNA analysis: Linking chemical composition, drug loading, and morphology to in vitro efficacy while ensuring reproducibility across laboratories.
- High-throughput viral analytics: Utilizing emerging techniques to quantify rAAV virus titer, capsid content, and aggregation, despite current challenges in broad industrial adoption.
- Advanced mAb characterization: Employing chromatographic, electrophoretic, and electrochemical methods to ensure the purity and activity of monoclonal antibodies meet escalating quality control regulations.
- Multi-Attribute Methods (MAM): Utilizing high-resolution mass spectrometry to monitor multiple CQAs in a single injection, increasing laboratory throughput.
Regulatory frameworks for quality control in next‑generation therapeutics
The regulatory landscape for biologics is rapidly evolving, with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) providing increasingly specific guidance for advanced therapies. Quality control regulations are grounded in established ICH guidelines, such as Q2(R1) for analytical validation, Q6B for test procedures and acceptance criteria, or Q8-Q11 for a modern QbD approach. However, for nucleic acid-based therapies, regulators increasingly demand a case-by-case evaluation of the control strategy.
To meet these quality control regulations, laboratories must operate within an audit-ready lifecycle management system that prioritizes data integrity. In this digital era, best practices ensure that all electronic records and signatures meet 21 CFR Part 11 FDA requirements, guaranteeing that data is attributable, original, and protected from unauthorized alteration. These frameworks are further enhanced by privacy-preserving computational methods to secure sensitive genomic data across collaborative networks.
As the molecular complexity of your pipeline increases, having a partner who understands the nuance of nucleic acid therapeutics is vital. At AMSbiopharma, we offer specialized support in designing and implementing fit-for-purpose quality control protocols tailored to the unique challenges of biologics and nucleic acid-based medicines.
From early-phase method qualification to high-sensitivity impurity profiling using advanced techniques such as UPLC-MS/MS, our team ensures your quality control program is both technically robust and regulatory-compliant.
References
Daniel S, Kis Z, Kontoravdi C, Shah N. Quality by Design for enabling RNA platform production processes. Trends Biotechnol. 2022 Oct;40(10):1213-1228. doi: 10.1016/j.tibtech.2022.03.012
Gonzalez JC, Park KW, Evans DB, Sharma R, Sahaym O, Gopalakrishnan S, Dar AI, Valdez TA, Sharma A. Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Mar-Apr;17(2):e70010. doi: 10.1002/wnan.70010
International Council for Harmonisation (ICH). ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology – Scientific guideline [Internet]. Ginebra: ICH; 1996 Nov [cited 2026 Ene 20]. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf
U.S. Food and Drug Administration (FDA). Part 11, Electronic Records; Electronic Signatures — Scope and Application – Guidance for Industry [Internet]. Silver Spring (MD): FDA; 2003 Ago [cited 2026 Ene 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
Verch T, Campa C, Chéry CC, Frenkel R, Graul T, Jaya N, et al. Analytical quality by design, life cycle management, and method control. AAPS J. 2022;24(1):34. doi: 10.1208/s12248-022-00685-2
Yang F, Zhang J, Buettner A, Vosika E, Sadek M, Hao Z, Reusch D, Koenig M, Chan W, Bathke A, Pallat H, Lundin V, Kepert JF, Bulau P, Deperalta G, Yu C, Beardsley R, Camilli T, Harris R, Stults J. Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control. MAbs. 2023 Jan-Dec;15(1):2197668. doi: 10.1080/19420862.2023.2197668